These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
227 related articles for article (PubMed ID: 19623167)
1. Isotretinoin is not associated with inflammatory bowel disease: a population-based case-control study. Bernstein CN; Nugent Z; Longobardi T; Blanchard JF Am J Gastroenterol; 2009 Nov; 104(11):2774-8. PubMed ID: 19623167 [TBL] [Abstract][Full Text] [Related]
2. The association between corticosteroid use and development of fractures among IBD patients in a population-based database. Bernstein CN; Blanchard JF; Metge C; Yogendran M Am J Gastroenterol; 2003 Aug; 98(8):1797-801. PubMed ID: 12907335 [TBL] [Abstract][Full Text] [Related]
3. Acute gastroenteritis is followed by an increased risk of inflammatory bowel disease. García Rodríguez LA; Ruigómez A; Panés J Gastroenterology; 2006 May; 130(6):1588-94. PubMed ID: 16697722 [TBL] [Abstract][Full Text] [Related]
4. The Manitoba Inflammatory Bowel Disease Cohort Study: prolonged symptoms before diagnosis--how much is irritable bowel syndrome? Burgmann T; Clara I; Graff L; Walker J; Lix L; Rawsthorne P; McPhail C; Rogala L; Miller N; Bernstein CN Clin Gastroenterol Hepatol; 2006 May; 4(5):614-20. PubMed ID: 16630762 [TBL] [Abstract][Full Text] [Related]
5. Increased short- and long-term risk of inflammatory bowel disease after salmonella or campylobacter gastroenteritis. Gradel KO; Nielsen HL; Schønheyder HC; Ejlertsen T; Kristensen B; Nielsen H Gastroenterology; 2009 Aug; 137(2):495-501. PubMed ID: 19361507 [TBL] [Abstract][Full Text] [Related]
6. Inflammatory bowel diseases, 5-aminosalicylic acid and sulfasalazine treatment and risk of acute pancreatitis: a population-based case-control study. Munk EM; Pedersen L; Floyd A; Nørgård B; Rasmussen HH; Sørensen HT Am J Gastroenterol; 2004 May; 99(5):884-8. PubMed ID: 15128355 [TBL] [Abstract][Full Text] [Related]
7. The incidence of arterial thromboembolic diseases in inflammatory bowel disease: a population-based study. Bernstein CN; Wajda A; Blanchard JF Clin Gastroenterol Hepatol; 2008 Jan; 6(1):41-5. PubMed ID: 18063423 [TBL] [Abstract][Full Text] [Related]
8. The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory bowel disease: a population-based cohort study. Bernstein CN; Blanchard JF; Houston DS; Wajda A Thromb Haemost; 2001 Mar; 85(3):430-4. PubMed ID: 11307809 [TBL] [Abstract][Full Text] [Related]
9. The clustering of other chronic inflammatory diseases in inflammatory bowel disease: a population-based study. Bernstein CN; Wajda A; Blanchard JF Gastroenterology; 2005 Sep; 129(3):827-36. PubMed ID: 16143122 [TBL] [Abstract][Full Text] [Related]
10. Generational differences in the age at diagnosis with Ibd: genetic anticipation, bias, or temporal effects. Faybush EM; Blanchard JF; Rawsthorne P; Bernstein CN Am J Gastroenterol; 2002 Mar; 97(3):636-40. PubMed ID: 11922559 [TBL] [Abstract][Full Text] [Related]
11. Increased risk for demyelinating diseases in patients with inflammatory bowel disease. Gupta G; Gelfand JM; Lewis JD Gastroenterology; 2005 Sep; 129(3):819-26. PubMed ID: 16143121 [TBL] [Abstract][Full Text] [Related]
12. Use of pharmaceuticals by inflammatory bowel disease patients: a population-based study. Metge CJ; Blanchard JF; Peterson S; Bernstein CN Am J Gastroenterol; 2001 Dec; 96(12):3348-55. PubMed ID: 11774948 [TBL] [Abstract][Full Text] [Related]
13. Impact of Clostridium difficile on inflammatory bowel disease. Issa M; Vijayapal A; Graham MB; Beaulieu DB; Otterson MF; Lundeen S; Skaros S; Weber LR; Komorowski RA; Knox JF; Emmons J; Bajaj JS; Binion DG Clin Gastroenterol Hepatol; 2007 Mar; 5(3):345-51. PubMed ID: 17368234 [TBL] [Abstract][Full Text] [Related]
14. The incidence of inflammatory bowel disease in a rural region of Southern Germany: a prospective population-based study. Ott C; Obermeier F; Thieler S; Kemptner D; Bauer A; Schölmerich J; Rogler G; Timmer A Eur J Gastroenterol Hepatol; 2008 Sep; 20(9):917-23. PubMed ID: 18794607 [TBL] [Abstract][Full Text] [Related]
15. Does the use of 5-aminosalicylates in inflammatory bowel disease prevent the development of colorectal cancer? Bernstein CN; Blanchard JF; Metge C; Yogendran M Am J Gastroenterol; 2003 Dec; 98(12):2784-8. PubMed ID: 14687833 [TBL] [Abstract][Full Text] [Related]
16. The relationship between inflammatory bowel disease and socioeconomic variables. Bernstein CN; Kraut A; Blanchard JF; Rawsthorne P; Yu N; Walld R Am J Gastroenterol; 2001 Jul; 96(7):2117-25. PubMed ID: 11467642 [TBL] [Abstract][Full Text] [Related]
17. 5-aminosalicylate is not chemoprophylactic for colorectal cancer in IBD: a population based study. Bernstein CN; Nugent Z; Blanchard JF Am J Gastroenterol; 2011 Apr; 106(4):731-6. PubMed ID: 21407180 [TBL] [Abstract][Full Text] [Related]
18. Relationship between clinical parameters and the colitis-colorectal cancer interval in a cohort of patients with colorectal cancer in inflammatory bowel disease. Brackmann S; Andersen SN; Aamodt G; Langmark F; Clausen OP; Aadland E; Fausa O; Rydning A; Vatn MH Scand J Gastroenterol; 2009; 44(1):46-55. PubMed ID: 18609187 [TBL] [Abstract][Full Text] [Related]
19. IL-1 receptor antagonist (IL-1Ra) gene polymorphism in patients with inflammatory bowel disease in India. Mittal RD; Bid HK; Ghoshal UC Scand J Gastroenterol; 2005 Jul; 40(7):827-31. PubMed ID: 16109659 [TBL] [Abstract][Full Text] [Related]
20. Risk of arterial thrombotic events in inflammatory bowel disease. Ha C; Magowan S; Accortt NA; Chen J; Stone CD Am J Gastroenterol; 2009 Jun; 104(6):1445-51. PubMed ID: 19491858 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]